Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, medical-device maker Becton, Dickinson and Co. (NYSE: BDX) has earned a coveted five-star ranking.

With that in mind, let's take a closer look at Becton Dickinson's business and see what CAPS investors are saying about the stock right now.

Becton Dickinson facts

Headquarters (Founded) Franklin Lakes, N.J. (1897)
Market Cap $16.0 billion
Industry Health-care equipment
Trailing-12-Month Revenue $7.8 billion
Management CEO Vincent Forlenza (since October 2011)
CFO David Elkins (since December 2008)
Return on Equity (Average, Past 3 Years) 23.3%
Cash/Debt $1.6 billion / $2.7 billion
Dividend Yield 2.5%
Competitors Abbott Labs
Baxter International
Covidien

Sources: S&P Capital IQ and Motley Fool CAPS.

On CAPS, 98% of the 1,125 members who have rated Becton Dickinson believe the stock will outperform the S&P 500 going forward.

Just last month, one of those Fools, THemler, highlighted the stock as a solid all-purpose play:

Bought [Becton Dickinson] both as short-term defensive & long-term growth prospect. The upside/downside ratio is favorable at current levels. Company is well positoned to grow in emerging markets, but must adjust product costs to truly compete. I'm betting on [Becton Dickinson] management to figure it al out and resume their historic consistant growth.

What do you think about Becton Dickinson, or any other stock for that matter? If you want to retire rich, you need to put together the best portfolio you can. Owning exceptional stocks is a surefire way to secure your financial future, and on Motley Fool CAPS, thousands of investors are working every day to find them. CAPS is 100% free, so get started!

Want to see how well (or not so well) the stocks in this series are performing? Follow the new TrackPoisedTo CAPS account.  

Fool contributor Brian Pacampara owns no position in any of the companies mentioned. Motley Fool newsletter services have recommended buying shares of Becton Dickinson, Abbott, and Covidien. The Fool owns shares of Abbott. Try any of our Foolish newsletter services free for 30 days

We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Fool's disclosure policy always gets a perfect score.